Germany Huntingtons Disease Treatment Market Size & Outlook
Related Markets
Germany huntingtons disease treatment market highlights
- The Germany huntingtons disease treatment market generated a revenue of USD 34.5 million in 2024 and is expected to reach USD 117.8 million by 2030.
- The Germany market is expected to grow at a CAGR of 21.9% from 2025 to 2030.
- In terms of segment, symptomatic treatment was the largest revenue generating treatment in 2024.
- Symptomatic Treatment is the most lucrative treatment segment registering the fastest growth during the forecast period.
Huntingtons disease treatment market data book summary
| Market revenue in 2024 | USD 34.5 million |
| Market revenue in 2030 | USD 117.8 million |
| Growth rate | 21.9% (CAGR from 2025 to 2030) |
| Largest segment | Symptomatic treatment |
| Fastest growing segment | Symptomatic Treatment |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Symptomatic Treatment |
| Key market players worldwide | H. Lundbeck AS Class A, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Hetero, Lupin, Hikma Pharmaceuticals PLC, Dr Reddy's Laboratories Ltd ADR, Sun Pharmaceutical Industries |
Other key industry trends
- In terms of revenue, Germany accounted for 6.9% of the global huntingtons disease treatment market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, UK huntingtons disease treatment market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 118.1 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Huntingtons Disease Treatment Market Scope
Huntingtons Disease Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Hetero | View profile | 10001+ | Hyderabad, Andhra Pradesh, India, Asia | https://www.hetero.com/ |
| H. Lundbeck AS Class A | View profile | 5700 | Ottiliavej 9, Valby, Denmark, 2500 | https://www.lundbeck.com |
| Hikma Pharmaceuticals PLC | View profile | 2150 | 1 New Burlington Place, London, United Kingdom, W1S 2HR | https://www.hikma.com |
| Bausch Health Companies Inc | View profile | 20270 | 2150 Saint Elzear Boulvard West, Laval, QC, Canada, H7L 4A8 | https://www.bauschhealth.com |
| Sun Pharmaceutical Industries | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | http://www.sunpharma.com |
| Lupin | View profile | 10001+ | Mumbai, Maharashtra, India, Asia | https://www.lupin.com |
| Dr Reddy's Laboratories Ltd ADR | View profile | 22822 | 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, India, 500 034 | https://www.drreddys.com |
| Teva Pharmaceutical Industries Ltd | View profile | 37851 | 124 Dvora HaNevi’a Street, Tel Aviv, Israel, 6944020 | https://www.tevapharm.com |
Germany huntingtons disease treatment market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to huntingtons disease treatment market will help companies and investors design strategic landscapes.
Symptomatic treatment was the largest segment with a revenue share of 126.96% in 2024. Horizon Databook has segmented the Germany huntingtons disease treatment market based on symptomatic treatment covering the revenue growth of each sub-segment from 2018 to 2030.
The Huntington’s disease treatment market in Germany is expected to witness significant growth over the forecast period owing to high burden of the disease, availability of symptom management products, and expected entry of potential disease modifying therapies in the market. Huntexil (pridopidine), which is developed by Prilenia Therapeutics B.V., is expected to enter Germany Huntington’s disease treatment market in 2026.
According to Institute for Applied Health Research Berlin, the period prevalence of HD was reported to be around 9.3 per 100,000 of the population. In addition, the article suggests that around 66.9% patients receive antipsychotics that cost USD 640 per year, out of which Tiapride was prescribed to around 46.8% of HD patients.
Moreover, antidepressants were prescribed to around 45.1% patients, with USD 141.43 annual cost per patient. The most prescribed antidepressant was mirtazapine, accounting for 20.5% of HD patients. However, these drugs do not cure the disease but are used for symptom management in patients.
Reasons to subscribe to Germany huntingtons disease treatment market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Germany huntingtons disease treatment market databook
-
Our clientele includes a mix of huntingtons disease treatment market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany huntingtons disease treatment market , including forecasts for subscribers. This country databook contains high-level insights into Germany huntingtons disease treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Germany huntingtons disease treatment market size, by treatment, 2018-2030 (US$M)
Germany Huntingtons Disease Treatment Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
